United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - imipramine pamoate (unii: mc34p30298) (imipramine - unii:ogg85sx4e4) - imipramine pamoate 75 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. the use of maois intended to treat psychiatric disorders with imipramine pamoate or within 14 days of stopping treatment with imipramine pamoate is contraindicated because of an increased risk of serotonin syndrome. the use of imipramine pamoate within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration). starting imipramine pamoate in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration). the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the

Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - imipramine hydrochloride - coated tablet - imipramine hydrochloride 25 mg - psychoanaleptics

United States - English - NLM (National Library of Medicine)

excellium pharmaceutical, inc - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride tablets usp in patients receiving a monoamine oxidase inhibitor, as long an interval should elap

United States - English - NLM (National Library of Medicine)

avkare - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis - may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride tablets usp in patients receiving a monoamine oxidase inhibi

United States - English - NLM (National Library of Medicine)

a-s medication solutions - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 25 mg - depression - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis - may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride in patients receiving a monoamine oxidase inhibitor, as long

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 10 mg - tablet, sugar coated - excipient ingredients: macrogol 8000; povidone; stearic acid; hypromellose; purified talc; glycerol; magnesium stearate; titanium dioxide; maize starch; microcrystalline cellulose; iron oxide red; colloidal anhydrous silica; lactose monohydrate; sucrose; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 25 mg - tablet, sugar coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; colloidal anhydrous silica; sucrose; magnesium stearate; stearic acid; lactose monohydrate; hypromellose; maize starch; glycerol; povidone; iron oxide red; macrogol 8000; carnauba wax; purified talc; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc.,usa - trimipramine maleate (unii: 269k6498ld) (trimipramine - unii:6s082c9ndt) - trimipramine maleate capsules are indicated for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. in studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. in hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. the use of maois intended to treat psychiatric disorders with trimipramine maleate or within 14 days of stopping treatment with trimipramine maleate is contraindicated because of an increased risk of serotonin syndrome. the use of trimipramine maleate within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting trimipramine maleate in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also co

United States - English - NLM (National Library of Medicine)

epic pharma, llc - trimipramine maleate (unii: 269k6498ld) (trimipramine - unii:6s082c9ndt) - trimipramine maleate capsules are indicated for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. in studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. in hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. the use of maois intended to treat psychiatric disorders with trimipramine maleate or within 14 days of stopping treatment with trimipramine maleate is contraindicated because of an increased risk of serotonin syndrome. the use of trimipramine maleate within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting trimipramine maleate in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also co

United States - English - NLM (National Library of Medicine)

elite laboratories, inc. - trimipramine maleate (unii: 269k6498ld) (trimipramine - unii:6s082c9ndt) - trimipramine maleate capsules are indicated for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. in studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. in hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. the use of maois intended to treat psychiatric disorders with trimipramine maleate or within 14 days of stopping treatment with trimipramine maleate is contraindicated because of an increased risk of serotonin syndrome. the use of trimipramine maleate within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting trimipramine maleate in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also co